Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CASSAVA SCIENCES INC (PTIE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates"
07/05/2023 8-K Quarterly results
05/08/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/01/2023 8-K Quarterly results
05/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/01/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 8-K Quarterly results
Docs: "Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates"
03/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2023 ARS Form ARS - Annual Report to Security Holders:
03/16/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates"
02/08/2023 SC 13G/A CASSAVA SCIENCES INC reports a 4.7% stake in Cassava Sciences, Inc.
02/07/2023 5 BARBIER REMI (President and CEO) has filed a Form 5 on CASSAVA SCIENCES INC
01/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease"
01/03/2023 5 FRIEDMANN NADAV (Chief Medical Officer) has filed a Form 5 on CASSAVA SCIENCES INC
12/22/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF CASSAVA SCIENCES, INC."
11/22/2022 8-K Quarterly results
11/21/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates – $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected –"
11/03/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
09/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study"
07/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cassava Sciences, Inc."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy